Can go travel soon

Final results from Pfizer Inc's COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday.

The vaccine's efficacy rate, the highest of any candidate in late-stage clinical trials so far, pleased experts who had already said that interim results showing Pfizer's shot was over 90% effective were very encouraging.

Final results from Pfizer Inc's COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday.

The vaccine's efficacy rate, the highest of any candidate in late-stage clinical trials so far, pleased experts who had already said that interim results showing Pfizer's shot was over 90% effective were very encouraging.

Final results from Pfizer Inc's COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday.

The vaccine's efficacy rate, the highest of any candidate in late-stage clinical trials so far, pleased experts who had already said that interim results showing Pfizer's shot was over 90% effective were very encouraging.

Final results from Pfizer Inc's COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday.

The vaccine's efficacy rate, the highest of any candidate in late-stage clinical trials so far, pleased experts who had already said that interim results showing Pfizer's shot was over 90% effective were very encouraging.

Final results from Pfizer Inc's COVID-19 vaccine trial showed its shot had a 95% success rate and two months of safety data, paving the way for the drugmaker to apply for an emergency U.S. authorization within days, it said on Wednesday.

The vaccine's efficacy rate, the highest of any candidate in late-stage clinical trials so far, pleased experts who had already said that interim results showing Pfizer's shot was over 90% effective were very encouraging.

KUALA LUMPUR: The government should introduce a “windfall tax” on companies that have raked in extraordinary profits during the Covid-19 pandemic, says Muar MP Syed Saddiq Syed Abdul Rahman.

He said several glove companies had raked in billions of ringgit this year following high global demand due to the pandemic.

He added that they should be subjected to a windfall tax which could be channelled to the purchase of Covid-19 vaccines and to assist frontliners.

“My proposal is for the government to introduce a windfall tax on rubber glove companies in Malaysia that have enjoyed extraordinary profits in the Covid-19 season.

“We do not want to punish the companies but they have raked in extraordinary profits when others are suffering, ” he said while debating Budget 2021 in the Dewan Rakyat here on Wednesday (Nov 18).

Syed Saddiq said the government should be brave enough to introduce a fair taxation system for the benefit of the people.

“Do not let the rich become richer and the poor remain poor, ” he said.

The former youth and sports minister said the government had received RM400mil in the form of items donated by these companies.

During the tabling of Budget 2021, Finance Minister Tengku Datuk Seri Zafrul Abdul Aziz said the contribution would help to cover the cost of Covid-19 vaccines as well as health equipment expenses.

KUALA LUMPUR: The government should introduce a “windfall tax” on companies that have raked in extraordinary profits during the Covid-19 pandemic, says Muar MP Syed Saddiq Syed Abdul Rahman.

He said several glove companies had raked in billions of ringgit this year following high global demand due to the pandemic.

He added that they should be subjected to a windfall tax which could be channelled to the purchase of Covid-19 vaccines and to assist frontliners.

“My proposal is for the government to introduce a windfall tax on rubber glove companies in Malaysia that have enjoyed extraordinary profits in the Covid-19 season.

“We do not want to punish the companies but they have raked in extraordinary profits when others are suffering, ” he said while debating Budget 2021 in the Dewan Rakyat here on Wednesday (Nov 18).

Syed Saddiq said the government should be brave enough to introduce a fair taxation system for the benefit of the people.

“Do not let the rich become richer and the poor remain poor, ” he said.

The former youth and sports minister said the government had received RM400mil in the form of items donated by these companies.

During the tabling of Budget 2021, Finance Minister Tengku Datuk Seri Zafrul Abdul Aziz said the contribution would help to cover the cost of Covid-19 vaccines as well as health equipment expenses.

KUALA LUMPUR: The government should introduce a “windfall tax” on companies that have raked in extraordinary profits during the Covid-19 pandemic, says Muar MP Syed Saddiq Syed Abdul Rahman.

He said several glove companies had raked in billions of ringgit this year following high global demand due to the pandemic.

He added that they should be subjected to a windfall tax which could be channelled to the purchase of Covid-19 vaccines and to assist frontliners.

“My proposal is for the government to introduce a windfall tax on rubber glove companies in Malaysia that have enjoyed extraordinary profits in the Covid-19 season.

“We do not want to punish the companies but they have raked in extraordinary profits when others are suffering, ” he said while debating Budget 2021 in the Dewan Rakyat here on Wednesday (Nov 18).

Syed Saddiq said the government should be brave enough to introduce a fair taxation system for the benefit of the people.

“Do not let the rich become richer and the poor remain poor, ” he said.

The former youth and sports minister said the government had received RM400mil in the form of items donated by these companies.

During the tabling of Budget 2021, Finance Minister Tengku Datuk Seri Zafrul Abdul Aziz said the contribution would help to cover the cost of Covid-19 vaccines as well as health equipment expenses.

KUALA LUMPUR: The government should introduce a “windfall tax” on companies that have raked in extraordinary profits during the Covid-19 pandemic, says Muar MP Syed Saddiq Syed Abdul Rahman.

He said several glove companies had raked in billions of ringgit this year following high global demand due to the pandemic.

He added that they should be subjected to a windfall tax which could be channelled to the purchase of Covid-19 vaccines and to assist frontliners.

“My proposal is for the government to introduce a windfall tax on rubber glove companies in Malaysia that have enjoyed extraordinary profits in the Covid-19 season.

“We do not want to punish the companies but they have raked in extraordinary profits when others are suffering, ” he said while debating Budget 2021 in the Dewan Rakyat here on Wednesday (Nov 18).

Syed Saddiq said the government should be brave enough to introduce a fair taxation system for the benefit of the people.

“Do not let the rich become richer and the poor remain poor, ” he said.

The former youth and sports minister said the government had received RM400mil in the form of items donated by these companies.

During the tabling of Budget 2021, Finance Minister Tengku Datuk Seri Zafrul Abdul Aziz said the contribution would help to cover the cost of Covid-19 vaccines as well as health equipment expenses.

Tan Choon Wah is coming ?

Tomorrow limit up ?

Tan Choon Hwa Is the new major shareholder ?

If not because of company buyback, Topglov might sink to 5.00 now

Game over

Wow managed to buy at 14 cents 500 lots. Waiting for 23 cents to sell. Huat ar...

More covid cases coming just like what happened to Kluster Damanlela and in workers hostel in Singapore. May affect the whole operation of Topglov. Better don't rush in to buy now.

https://www.malaysiakini.com/news/551362?utm_source=dlvr.it&utm_medium=facebook

Music going to end soon...joining Anzo, Inix and PDZ soon

Music going to end soon...joining Anzo and PDZ soon

HLIB’s VIEW
Slight disruption. We understand that Top Glove’s factories will be running as usual despite the lesser workers during the EMCO on the on the 2 dormitories. Despite so, we reckon that some production disruption can be reasonably expected during the 14 day EMCO period. The 2 dormitories comprise c.2.5k workers, or 16% of Top Glove’s total factory workers. Top Glove is still in the midst of seeking further clarification with relevant authorities on the implementation of this EMCO.

Vaccine development. Last week, it was reported that a vaccine jointly developed by Pfizer and BioNTech was 90% effective in preventing Covid-19 in its ongoing Phase 3 trials. Separately yesterday, Moderna said preliminary Phase 3 trial data showed its vaccine is more than 94% effective in preventing Covid-19.

Forecast. We decrease our FY21 earnings by -3.8% to reflect in the temporary disruption from the EMCO.

Maintain BUY, TP: RM10.95. With the hype on vaccine discovery closing in, we lower our PE target from 16x to 14x (reflecting -1.5SD below 5Y mean, from -1SD previously), still tagged to FY21 EPS. Alongside with the earnings adjustments, TP decreases to RM10.95 (from RM13.00). With share price having declined c.25% since Oct 19, we nonetheless still think there is sufficient buffer to warrant our BUY rating.

Yesterday, Senior Minister (Security Cluster) Datuk Seri Ismail Sabri Yaakob announced that Top Glove’s workers dormitory and the surrounding area will be placed under an enhanced movement control order (EMCO) beginning 17 Nov 2020.
The affected area is the male workers’ dormitory and Jalan Abadi 1A/KU8, and the female workers’ dormitory as well as Jalan Abadi 1A and Jalan Abadi 10/KU8. The lockdown involves 13,190 workers and close to 1,200 residents.
Meanwhile, Top Glove said the company will seek clarification with the relevant authorities with regards to the implementation of the EMCO from 17 Nov to 30 Nov 2020. The company has revealed that the total number of workers affected by the EMCO is 2,500 people, representing 15% of total workforce.
Based on our rough estimate, with 15% of workforce affected by the 14-day quarantine, the impact to Top Glove’s bottom line is less than 1%, which is insignificant. Hence, we are not making any changes to our earnings forecasts. Maintain HOLD with an unchanged fair value of RM7.88 per share based on 5-year average PER of 28x

11.00 coming soon after EMCO

15.00 coming soon

Ppl already cashed out from glove stocks...some daydreamers still chasing AT, Gets and Mtronic, crashing down soon. Beware !!

Bursa too happy not to act... welcome to the biggest manipulation in bursamalaysia.

KYY also become AT promoter...sell Supermx and Topglov !

Glove happy hour almost over... still haven't sell any glove ?

Suddenly so many ball licking article about at

Fake hope... save your hard-earned money

Fake story all around

Going to sell my house to buy this stock

KYY influence not as great as TCH...even only with the name TCH also can make mtronic a top gainer.

Congrats to all mtronic shareholders...your big boss now is a super kaki goreng. More happy times ahead. 1.00 soon. Thanks Mr. TCH !

MACC should investigate Bursa's official for possible corruption just like what happened to police officials that protect the Macau scam.

WOW...Gets goreng kaki must have a very good connection with Bursa until no action taken even though the stock from 30 cents becomes 3.17 also nothing happen until now. UMA just for a show only from Bursa.

Party over ?

KUALA LUMPUR (Nov 12): AmInvestment Bank believes that while glove demand will stay stable post-Covid-19 pandemic, average selling prices (ASPs) will drop as there will no longer be a rush for gloves.

“We reckon that ASP will stabilise at a higher level than pre-pandemic level due to the broader usage of gloves,” it said in a note on Top Glove Corp Bhd today.

The research house’s analyst Thong Pak Leng said it believed that glove demand will remain strong, based on reasons outlined by Top Glove during a webinar, which include a higher awareness of personal hygiene and broader use of gloves beyond the healthcare sector.

In addition, Thong said there may not be an oversupply of gloves after the pandemic, as Top Glove had pointed out that there are key issues in ramping up supply that need to be addressed, including the availability of contractors to build production lines, the shortage of foreign workers and constraint of nitrile raw material.

Top Glove has also allocated 30% of its capacity for spot orders. “The spot orders for nitrile glove have been fully sold for the next three months. Meanwhile, the spot orders for natural rubber powder-free gloves are also increasing due to the long lead time of nitrile gloves,” said Thong.

Presently, Top Glove has a total production capacity of 90 billion pieces per annum.

To expand further, Top Glove has allocated capital expenditure of RM10 billion over the next five years for capacity expansion to double its current capacity by the end of 2025, said Thong. This will be done in stages whereby 14 billion pieces will be added for FY21 and 16 billion for FY22.

AmInvestment Bank maintains its "hold" call on the stock with a lower fair value of RM7.88, adding that the group’s fundamentals remain solid for the next few years.

“We maintain our view that Top Glove’s net profit will peak in FY21 as demand soars from the Covid-19 pandemic with increased capacity expansions. We make no changes to our FY21–FY23 net profit forecasts at RM6.5 billion, RM2.3 billion and RM2.2 billion respectively.

“Our ASP assumptions are US$60 per 1,000 pieces for FY21, US$35 per 1,000 pieces for FY22 and US$28 per 1,000 pieces for FY23 with an average utilisation rate of more than 80%,” said Thong.

No joy for glove stocks... most penny and speculative stocks went up. Tomorrow it's oil and gas stocks. Get ready for the big bucks. Forget about glove stocks.

No joy for glove stocks... most penny and speculative stocks went up. Tomorrow it's oil and gas stocks. Get ready for the big bucks. Forget about glove stocks.

No joy for glove stocks... most penny and speculative stocks went up. Tomorrow it's oil and gas stocks. Get ready for the big bucks. Forget about glove stocks.

No joy for glove stocks... most penny and speculative stocks went up. Tomorrow it's oil and gas stocks. Get ready for the big bucks. Forget about glove stocks.

No joy for glove stocks... most penny and speculative stocks went up. Tomorrow it's oil and gas stocks. Get ready for the big bucks. Forget about glove stocks.

No joy for glove stocks... most penny and speculative stocks went up. Tomorrow it's oil and gas stocks. Get ready for the big bucks. Forget about glove stocks.

No joy for glove stocks... most penny and speculative stocks went up. Tomorrow it's oil and gas stocks. Get ready for the big bucks. Forget about glove stocks.

KUALA LUMPUR: Shares in AT Systematization Bhd fell marginally in early trade after its acquisition of industrial glove maker has fallen through.

The precision engineering and industrial automation firm shed 1.85%, or 0.5 sen to 26.5 sen. It is the most active counter on Bursa Malaysia with 961 million shares done. AT-WC fell 2%, or 0.5 sen to 24.5 with 133 million shares traded.

AT Systematization said its RM22mil planned acquisition of industrial glove maker Pearl Glove Sdh Bhd has fallen through.

It said it has terminated the share sale agreement it inked in June with the vendors Hai Hong Capital Sdn Bhd, P’ng Sim Guan, P’ng Lai Heng, Hai Hong Holdings Sdn Bhd and Aaron Khoo Teng Soon for the purchase, due to the non- fulfilment of certain conditions.

Following the purchase cancellation, AT Systematization said it will be focusing on building up its own glove production capacity via the establishment of a new plant in Perak.

Very common scenerio....banker win player lose.

Moderna Inc said on Wednesday it has enough data for a first interim analysis of the late-stage trial of its experimental COVID-19 vaccine, which should help determine the vaccine's efficacy.

Moderna said the information is being prepared for submission to the trial's independent data safety monitoring board, which will look at the results and make a recommendation. It did not say when it plans to release the efficacy data.

The company said in a news release that it has seen a significant increase in the number of COVID-19 cases among trial participants as infection rates have surged around the United States.

Due to the spike in cases, the analysis will cover substantially more than 53 infections, which had been the targeted trigger point for the first analysis.

The company said the trial remains blinded, so neither it nor study investigators know which participants received the vaccine or a placebo. The vaccine will be deemed a success if the overwhelming majority of those infected had received a placebo, once the monitoring board looks at the early results.

Earlier in the day, Dr. Anthony Fauci, the top U.S. infectious disease expert, said Moderna could have the data from anywhere between "a couple of days" to "a little more than a week."

A high degree of effectiveness would make sense as it is "almost identical" to Pfizer Inc's experimental vaccine, Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said at a conference organized by the Financial Times.

"It may not be 95%, it might be 90%, or 96%, or 89%, but it is going to be up there," he said.

Pfizer on Monday said its COVID-19 vaccine was more than 90% effective based on interim trial results, significantly higher than the at least 50% efficacy regulators are looking for.

Moderna, which uses a similar messenger RNA technology as Pfizer, said earlier on Wednesday that its November timeline for initial data was on track.

It did not respond to a Reuters request for comment on when it would disclose the data.

The company would still have to wait for two-month follow-up safety data required by the U.S. Food and Drug Administration, which it expects to have in the second half of this month, before applying for U.S. emergency use authorization.

There are no vaccines that have gained global approval yet, although a handful, including Moderna's, are in late-stage studies.

Moderna's shares closed up 8.4% at $82.44 and rose to $83.85 in extended trading



Another vaccine results coming out soon. Beware to all glove lover and shareholders.

Moderna Inc said on Wednesday it has enough data for a first interim analysis of the late-stage trial of its experimental COVID-19 vaccine, which should help determine the vaccine's efficacy.

Moderna said the information is being prepared for submission to the trial's independent data safety monitoring board, which will look at the results and make a recommendation. It did not say when it plans to release the efficacy data.

The company said in a news release that it has seen a significant increase in the number of COVID-19 cases among trial participants as infection rates have surged around the United States.

Due to the spike in cases, the analysis will cover substantially more than 53 infections, which had been the targeted trigger point for the first analysis.

The company said the trial remains blinded, so neither it nor study investigators know which participants received the vaccine or a placebo. The vaccine will be deemed a success if the overwhelming majority of those infected had received a placebo, once the monitoring board looks at the early results.

Earlier in the day, Dr. Anthony Fauci, the top U.S. infectious disease expert, said Moderna could have the data from anywhere between "a couple of days" to "a little more than a week."

A high degree of effectiveness would make sense as it is "almost identical" to Pfizer Inc's experimental vaccine, Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said at a conference organized by the Financial Times.

"It may not be 95%, it might be 90%, or 96%, or 89%, but it is going to be up there," he said.

Pfizer on Monday said its COVID-19 vaccine was more than 90% effective based on interim trial results, significantly higher than the at least 50% efficacy regulators are looking for.

Moderna, which uses a similar messenger RNA technology as Pfizer, said earlier on Wednesday that its November timeline for initial data was on track.

It did not respond to a Reuters request for comment on when it would disclose the data.

The company would still have to wait for two-month follow-up safety data required by the U.S. Food and Drug Administration, which it expects to have in the second half of this month, before applying for U.S. emergency use authorization.

There are no vaccines that have gained global approval yet, although a handful, including Moderna's, are in late-stage studies.

Moderna's shares closed up 8.4% at $82.44 and rose to $83.85 in extended trading



Another vaccine results coming out soon. Beware to all glove lover and shareholders.

Moderna Inc said on Wednesday it has enough data for a first interim analysis of the late-stage trial of its experimental COVID-19 vaccine, which should help determine the vaccine's efficacy.

Moderna said the information is being prepared for submission to the trial's independent data safety monitoring board, which will look at the results and make a recommendation. It did not say when it plans to release the efficacy data.

The company said in a news release that it has seen a significant increase in the number of COVID-19 cases among trial participants as infection rates have surged around the United States.

Due to the spike in cases, the analysis will cover substantially more than 53 infections, which had been the targeted trigger point for the first analysis.

The company said the trial remains blinded, so neither it nor study investigators know which participants received the vaccine or a placebo. The vaccine will be deemed a success if the overwhelming majority of those infected had received a placebo, once the monitoring board looks at the early results.

Earlier in the day, Dr. Anthony Fauci, the top U.S. infectious disease expert, said Moderna could have the data from anywhere between "a couple of days" to "a little more than a week."

A high degree of effectiveness would make sense as it is "almost identical" to Pfizer Inc's experimental vaccine, Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said at a conference organized by the Financial Times.

"It may not be 95%, it might be 90%, or 96%, or 89%, but it is going to be up there," he said.

Pfizer on Monday said its COVID-19 vaccine was more than 90% effective based on interim trial results, significantly higher than the at least 50% efficacy regulators are looking for.

Moderna, which uses a similar messenger RNA technology as Pfizer, said earlier on Wednesday that its November timeline for initial data was on track.

It did not respond to a Reuters request for comment on when it would disclose the data.

The company would still have to wait for two-month follow-up safety data required by the U.S. Food and Drug Administration, which it expects to have in the second half of this month, before applying for U.S. emergency use authorization.

There are no vaccines that have gained global approval yet, although a handful, including Moderna's, are in late-stage studies.

Moderna's shares closed up 8.4% at $82.44 and rose to $83.85 in extended trading



Another vaccine results coming out soon. Beware to all glove lover and shareholders.

Moderna Inc said on Wednesday it has enough data for a first interim analysis of the late-stage trial of its experimental COVID-19 vaccine, which should help determine the vaccine's efficacy.

Moderna said the information is being prepared for submission to the trial's independent data safety monitoring board, which will look at the results and make a recommendation. It did not say when it plans to release the efficacy data.

The company said in a news release that it has seen a significant increase in the number of COVID-19 cases among trial participants as infection rates have surged around the United States.

Due to the spike in cases, the analysis will cover substantially more than 53 infections, which had been the targeted trigger point for the first analysis.

The company said the trial remains blinded, so neither it nor study investigators know which participants received the vaccine or a placebo. The vaccine will be deemed a success if the overwhelming majority of those infected had received a placebo, once the monitoring board looks at the early results.

Earlier in the day, Dr. Anthony Fauci, the top U.S. infectious disease expert, said Moderna could have the data from anywhere between "a couple of days" to "a little more than a week."

A high degree of effectiveness would make sense as it is "almost identical" to Pfizer Inc's experimental vaccine, Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, said at a conference organized by the Financial Times.

"It may not be 95%, it might be 90%, or 96%, or 89%, but it is going to be up there," he said.

Pfizer on Monday said its COVID-19 vaccine was more than 90% effective based on interim trial results, significantly higher than the at least 50% efficacy regulators are looking for.

Moderna, which uses a similar messenger RNA technology as Pfizer, said earlier on Wednesday that its November timeline for initial data was on track.

It did not respond to a Reuters request for comment on when it would disclose the data.

The company would still have to wait for two-month follow-up safety data required by the U.S. Food and Drug Administration, which it expects to have in the second half of this month, before applying for U.S. emergency use authorization.

There are no vaccines that have gained global approval yet, although a handful, including Moderna's, are in late-stage studies.

Moderna's shares closed up 8.4% at $82.44 and rose to $83.85 in extended trading



Another vaccine results coming out soon. Beware to all glove lover and shareholders.